XML 80 R136.htm IDEA: XBRL DOCUMENT v3.20.1
Equity - Reserves - Subsidiaries (Details)
€ in Thousands, EquityInstruments in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2019
EUR (€)
EquityInstruments
Jul. 31, 2019
EUR (€)
shares
Jun. 30, 2019
EUR (€)
Apr. 30, 2019
EUR (€)
Sep. 30, 2018
EUR (€)
shares
Jun. 30, 2018
EUR (€)
Oct. 31, 2017
EUR (€)
shares
Dec. 31, 2019
EUR (€)
EquityInstruments
shares
Dec. 31, 2018
EUR (€)
Dec. 31, 2017
EUR (€)
Aug. 31, 2018
May 31, 2018
Sep. 30, 2017
Equity                          
Increase (decrease) in working capital               € 481,537 € 112,639 € 65,800      
Increase (decrease) in reserves               1,716,147 € 465,548 € (389)      
Reserves                          
Equity                          
Increase (decrease) in reserves               € 227,000          
Araclon Biotech , S.L                          
Equity                          
share capital increases € 5,900     € 16,800                  
Grifols [Member]                          
Equity                          
Indirect (as a percent)       75.10%                  
Progenika Biopharma, S.A.                          
Equity                          
Increased capital   € 4     € 4,333                
Acquired Capital (in shares) | shares   33     41,387   12,020            
Indirect (as a percent)   100.00% 99.99%   99.99%   90.23%       96.64%   89.25%
Increase (decrease) in reserves             € (374,000)            
TiGenix | Reserves                          
Equity                          
Increase in reserves due to divestment           € 4,900              
TiGenix | Other comprehensive income                          
Equity                          
Decrease in other comprehensive income           4,900              
Ekarpen Private Equity, S.A                          
Equity                          
Increased capital           € 5,300              
Indirect (as a percent)           96.64%           90.23%  
Additional stake acquired (as a percent)           6.41%              
Kiro Grifols [Member]                          
Equity                          
Increase (decrease) in working capital     € 7,500                    
Proportion of ownership interests held by non-controlling interests     90.00%                    
Proportion of voting rights held by non-controlling interests     10.00%                    
GDS Group                          
Equity                          
Acquired Capital (in shares) | shares               90          
Increase (decrease) in reserves               € 227,000          
Consideration transferred, in shares | EquityInstruments 1,766             1,766          
Shanghai RAAS Blood Products, Co. Ltd.                          
Equity                          
Acquired Capital (in shares) | shares               0